Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Byoung Chul Cho et al.|The Lancet|2019Cited by 3.3k
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancerDaniel Betticher, N. Thatcher, Jim Heighway et al.|British Journal of Cancer|1996Cited by 220